Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

Abstract: Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises a soluble corticosteroid and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, or an intra-lesional injection.

Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.

Abstract: The present invention relates to polymers comprising a characteristic combination of alkylene amine moieties which are useful as vehicles for transfecting a cell with a nucleic acid. The present invention furthermore relates to a composition comprising a nucleic acid and such a polymer, and to a method of transfecting a cell using said composition. Furthermore, the present invention relates to pharmaceutical compositions and uses.

Abstract: Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.

Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

Abstract: In antibody-drug conjugates having tubulysin analog as the warhead, according to formula (III) the acetate group in the Tuv subunit (dotted box) demonstrates improved stability against hydrolytic cleavage.

Abstract: The present invention provides a biocompatible conjugate for treating a disease or an injury. The conjugate contains a polymer covalently linked to one or more moieties each containing a polymerizable functional group. The conjugate forms a cross-linked polymer network after being exposed to an elevated level of free radicals associated with the disease or injury.

Abstract: The present disclosure is in the field of genome engineering, particularly targeted integration of a functional SCID-related genes (e.g., IL2RG, RAG1 and/or RAG2 gene) into an IL2RG gene of a cell for provision of proteins lacking or deficient in SCID.

Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.

Abstract: The present disclosure provides non-human animal models of non-alcoholic fatty liver disease (NAFLD). Also provided are methods for producing the non-human animal models and uses of the non-human animal models to screen and evaluate agents for treating or preventing NAFLD.

Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.

Abstract: The present disclosure relates to compositions and methods for enhancing mosquito feeding.

Abstract: A rod-shaped plant virus having an interior surface and an exterior surface, and at least one imaging agent that is linked to the interior and/or exterior surface is described. The rod-shaped viruses can be combined into larger spherical nanoparticles. A rod-shaped plant virus or spherical nanoparticles including an imaging agent can be used in a method of generating an image of a tissue region of a subject such as a tumor or atherosclerotic tissue by administering the virus particle to the subject and generating an image of the tissue region of the subject to which the virus particle has been distributed.

Abstract: A method of destroying pathogens disposed upon an epidermis includes providing a hand held device including a grip and a lamp, transmitting far-UVC light via the lamp, and filtering the transmitted far-UVC light to attenuate portions of transmitted UVC light that have a wavelength known to cause damage to an epidermis of a human. The epidermis is scanned by tracing the hand held device over a localized area of the epidermis thereby illuminating the localized area with the filtered far-UVC light. The filtered far-UVC light destroys pathogens disposed upon the epidermis while not causing adverse biological damage to the epidermis.

Abstract: A vehicle comprising: a seating assembly; and a console disposed proximate the seating assembly. The console comprises a disinfection apparatus. The disinfection apparatus comprises a housing to accept items to be disinfected, and a source of ultraviolet radiation configured to emit ultraviolet radiation into the housing. In embodiments, the housing comprises a light guide operably coupled to at least one of a base and a lid, the light guide accepting the ultraviolet radiation from the source of the ultraviolet radiation and guiding the ultraviolet radiation within an interior chamber. In embodiments, the source of ultraviolet radiation is a light emitting diode configured to emit electromagnetic radiation having a peak intensity within a wavelength range of 200 nm to 300 nm.

Abstract: A disinfecting system includes a housing. An ultraviolet light (UV) source is secured to the housing and configured to emit UV light for disinfection of a target. A processor is secured to the housing in communication with the UV light source. The processor is configured to activate the UV light source for a selected amount of time suitable for disinfection of the target.

Abstract: A handheld light assembly for eradicating pathogens includes a housing. A processor and a lamp are disposed inside the housing. The lamp irradiates surfaces with disinfecting ultraviolet light having a peak wavelength of 222 nm filtered to restrict illumination to between 200 nm and 230 nm within an irradiation zone. A distance measuring system includes a secondary light source generating secondary light and a photodetector for measuring distance of the secondary light to a surface being irradiated by the lamp light being reflected from the surface to the photodetector. The secondary light source is offset at an angle from the lamp thereby projecting the light beam to a central area of the irradiation zone generated by the lamp. The photodetector signals the processor to calculate a vertical distance between the lamp and the central area of the irradiation zone on the surface being irradiated from an angular projection of the secondary light.

Abstract: Ultraviolet (UV) light emission devices and related methods of use. The UV light emission devices disclosed herein are particularly suited for use in disinfecting surfaces and air. The UV light emission devices disclosed herein can be provided in the form factor of a handheld device that is easily held and manipulated by a human user. The human user can manipulate the handheld UV light emission device to decontaminate surfaces, air, and other areas by orienting the handheld UV light emission device so that the UV light emitted from its light source is directed to the area of interest to be decontaminated.

Abstract: A disinfecting system includes a housing. An ultraviolet light (UV) source is secured to the housing and configured to emit UV light for disinfection of a target. A processor is secured to the housing in communication with the UV light source. The processor is configured to activate the UV light source for a selected amount of time suitable for disinfection of the target.

Abstract: Environmental sanitizing device including a frame housing a disinfectant liquid reservoir and supporting a nozzle, the nozzle associated with a generation system of an air flow within which a plurality of disinfectant liquid particles are suspended to sanitize a closed environment in which the device can be positioned; the nozzle is movable with respect to the frame, and associated with positioning system controlled by a control unit for orientation of the nozzle with respect to at least two mutually perpendicular axes, preferably around a first vertical axis and around a second horizontal axis to automatically orient the nozzle in desired direction with respect to the frame during a sanitization step, the nozzle coupled with at least one distance detector able to determine distance between the nozzle and an obstacle facing the nozzle.

Abstract: A method of sterilizing medical instruments using a vacuum chamber connected to reservoir by a valve in a closed state is disclosed that includes placing instruments in a non-sterile state into a sterilization pack, opening a chamber, placing the pack into the chamber, closing the chamber, withdrawing a first volume of air from the chamber, changing a volume of liquid water into vapor, opening the valve, introducing sterilant into the chamber, introducing a second volume of air into the chamber, opening the chamber, removing the pack from the chamber, and removing the instruments in a sterile-state from the pack. The process may further include the steps of repeatedly determining pressure within the chamber, calculating second-derivative values of pressure with respect to time, and determining whether any local maxima exist in a plot of second derivative values that correspond to pressures above and/or below the triple-point pressure of water.

Abstract: Provided is a decontamination apparatus that includes a motorized base with a transport system that is operable to autonomously move the decontamination apparatus. A plurality of UVC bulbs, each of which emits UVC light, are supported at a vertical elevation above the motorized base. A controller controls operation of the transport system to move the decontamination apparatus along a desired route while the UVC bulbs are energized during a decontamination process.

Abstract: An embodiment includes a wound dressing comprising: a shape memory polymer (SMP) foam, including open cells, having first and second states; and a hydrogel (HG) included within the cells; wherein (a) in a first position a composite, including the SMP foam and the HG, is configured to be located proximate a hemorrhagic tissue with the SMP foam in the first state; (b) in a second position the composite is configured to be expanded to the second state against the hemorrhagic tissue when the SMP foam is plasticized at 37° C. depressing a glass transition temperature (Tg) of the SMP foam to below 25° C. Other embodiments are described herein.

Abstract: Antimicrobial metal ion coatings and implants including them. In particular, described herein are coatings including an anodic metal (e.g., silver and/or zinc and/or copper) that is co-deposited with a cathodic metal (e.g., palladium, platinum, gold, molybdenum, titanium, iridium, osmium, rhodium, manganese, niobium or rhenium) on a substrate so that the anodic metal is galvanically released as antimicrobial ions when the apparatus is exposed to a bodily fluid. The anodic metal may be at least about 25 percent by volume of the coating, resulting in a network of anodic metal with less than 20% of the anodic metal in the coating fully encapsulated by cathodic metal. The implant may be configured as an implant such as a bone-screw or intramedullary rod-like body configured to receive a treatment cartridge having a coating as described.

Abstract: A biopolymer fiber containing collagen. The biopolymer fiber has excellent ultimate tensile strength, modulus of elasticity, and strain at break comparable to native human tendons and ligaments. The fiber may substantially circular, ovoid, square, rectangular, ribbon-like, triangular, or irregularly shaped. The fiber exhibits an ordered, longitudinally-oriented structure, and the fiber allows infiltration of cellular growth. Implantable biopolymer scaffolds and sutures containing the fibers are provided as well as microfluidic and extrusion methods for producing the biopolymer fibers.

Abstract: Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

Abstract: A device includes a substrate and a hydrophilic polymer layer made of a hydrophilic polymer having a hydroxyl group. The hydrophilic polymer layer having a hydroxyl group is fixed to at least a part of a surface of the substrate and the hydrophilic polymer further has an amide group. A liquid film retention time of the device is 15 seconds or more. The device has a surface of a substrate which is hydrophilized. A method for producing the device by a simple method is also disclosed.

Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Abstract: The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject.

Abstract: An absorbable iron-based alloy medical device implant, comprising an iron-based alloy substrate (11) and a degradable polymer (13) provided on a surface of an iron-based alloy substrate (11), and a zinc-containing protective member (12) provided on the surface of the iron-based alloy substrate (11). The zinc-containing protective member (12) is either a zinc compound or a mixture comprising the zinc compound and at least one of a phosphate-containing compound, a degradable binder, or a water-soluble binder. The weight ratio of the zinc compound in the mixture is ?20% and <100%. The zinc-containing protective member (12) can delay corrosion of the iron-based alloy substrate (11) during an early stage of medical device implantation. The iron-based alloy substrate (11) is essentially corrosion-free during the early stage of medical device implantation, and is therefore able to satisfy clinical requirements of mechanical performance during the early stage of medical device implantation.

Abstract: A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

Abstract: A reduced pressure dressing for applying reduced pressure treatment to a tissue site includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site, and a liquid-air separator is positioned between the absorbent layer and the pump to inhibit liquid from entering the pump.

Abstract: Blood treatment apparatus and methods of using the same are described herein that include two or more intermediate containers located between a treatment solution source and a port through which the treatment solution is to be delivered with the blood treatment apparatus. The weight of the intermediate containers is measured and used to control the refilling and emptying of treatment solution in the intermediate containers.

Abstract: An apparatus for extracorporeal blood treatment comprises a sensor (10) for emitting a signal indicating a variation in blood volume (?Bv?) of an individual (7) subjected to extracorporeal blood treatment and a sensor (14) for emitting a signal indicating a weight loss of the individual. A control unit (20) receives the signals, compares the ratio between the relative variation of blood volume (?Bv/BV) and the relative variation of weight loss (AWL/TW) of the individual with a desired value, and controls the weight loss of the individual on the basis of the comparison. The apparatus enables automatically controlling a dialysis, preventing some complications due to hypotension.

Abstract: Systems and methods for providing multiple pass continuous flow dialysis are provided. In an embodiment, a system for providing peritoneal dialysis includes a catheter in communication with a peritoneal cavity, a fluid loop in fluid communication with the catheter and capable of circulating a therapy fluid into, through and out of the patient's peritoneal cavity, a multi-line fluid circuit, the multi-line fluid circuit in fluid communication with the fluid loop and including a bypass line coupled to a discharge fluid line, and a cycler including a plurality of valves, the cycler programmed to operate the plurality of valves to selectively (i) discharge therapy fluid from the multi-line fluid circuit via the discharge fluid line or (ii) bypass the discharge fluid line via the bypass line and circulate the therapy fluid a plurality of times through the fluid loop prior to exiting the multi-line fluid circuit via the discharge fluid line.

Abstract: The present invention is a sterile peritoneal dialysis fluid, including an acidic first liquid containing only icodextrin and 0 to 2.34 g/L of sodium chloride, and an alkaline second liquid containing an alkaline pH regulator, in which the first liquid after sterilization has a pH of 5.0 to 5.5, the second liquid after sterilization has a pH of 6.5 to 7.5, and a mixture of the first liquid and the second liquid after sterilization has a pH of 6.0 to 7.5. The present invention can provide a peritoneal dialysis fluid containing icodextrin, in which the stability of icodextrin during the heat sterilization and the subsequent storage can be improved to the maximum, and the pH of the peritoneal dialysis fluid is close to the physiological range.

Abstract: The invention concerns methods of removing undesirable molecules from the blood or physiologic fluid; said method comprising contacting said blood or physiologic fluid with a sorbent, said sorbent comprising a plurality of solid forms and comprising a cross-linked polymeric material having a plurality of ligands attached to the surface of said cross-linked polymeric material, comprising (i) zwitterionic moieties, (ii) oligo(ethylene glycol) moieties or (iii) mixtures thereof; said contacting comprising said sorbent sorbing a plurality of said undesirable molecules when said sorbent is administered within a patient's body.

Abstract: Devices, methods, and systems are provided for priming, separating, and collecting blood components. At least one disposable component may be utilized, and a determination may be made as to whether such a disposable component is authentic, is new/unused or used, or both.

Abstract: A canister stand suitable for holding at least one dispensing canister in a system for removal, delivery and/or transplantation of body tissues and other substances in medical procedures may include a canister stand frame. A frame panel may be carried by the canister stand frame. At least one overhang may be formed by the canister stand frame. At least one canister opening may be provided in the frame panel at the at least one overhang. The at least one canister opening may be suitably sized and configured to accommodate the at least one dispensing canister.

Abstract: In one embodiment, a peristaltic micropump comprising a substrate having a first side and a second side, a microtube that extends across the first side of the substrate, and multiple pump actuators formed on the first side of the substrate and positioned adjacent to the microtube at discrete, spaced positions along the length of the microtube, wherein the micropump is configured to sequentially actuate the pump actuators so as to create peristaltic action that drives fluid contained in the microtube along the length of the tube.

Abstract: An injector includes an injector housing and a cartridge door movably mounted to the injector housing between a fully closed position and an open position. A latching mechanism is movable between a latched position, locking the cartridge door to the injector housing in the fully closed position thereof, and an unlatched position, unlocking the cartridge door from the injector housing, thereby enabling movement of the cartridge door toward the open position. The latching mechanism is oriented in the unlatched position when the cartridge door is empty and the latching mechanism is configured to move to the latched position solely when a cartridge is present in the cartridge door and the cartridge door is subsequently moved to the fully closed position thereof.

Abstract: An infusion device (50) incl. a preferably soft cannula (1) configured to be inserted by means of an insertion needle. The cannula has a tubular body member having a proximal end and a subcutaneously placed distal portion having a distal end where the distal portion is provided with an opening (2) allowing a portion of a drug conveyed through the tubular body member to discharge. The cannula further comprise, in the distal portion, a radial opening allowing a portion of a drug conveyed through the tubular body member to discharge.

Abstract: An injector is provided for performing an injection operation comprising a housing (104), a needle extendable from a front end of the housing, a rear end of the housing and a longitudinal axis extending between the front end and the rear end, a safety pin (116) in an actuation locked position coupled to the housing and moveable to a safety released position coupled to the housing. The injector is locked against actuation when the safety pin is in the actuation locked position and the injector is ready for actuation of the injection operation when the safety pin is in the safety released position.

Abstract: An automatic injection device configured for injection of a material stored in a syringe into an injection site, the syringe including a generally cylindrical storage container and a piston disposed therewithin, whose exact initial axial position within the container is not predetermined, wherein axial forward displacement of the piston in the container forces the material forwardly out of the container, the automatic injection device including at least one spring drive assembly operative, when actuated, to initially apply a first axial force to the syringe, thereby to axially displace the syringe in a forward direction, and thereafter, responsive to driving engagement with the piston, to apply a second axial force, substantially greater than the first axial force, notwithstanding the fact that the exact axial position of the piston within the container is not predetermined, to the piston, thereby to axially forwardly displace the piston relative to the syringe.

Abstract: In one aspect the present disclosure relates to a sensor for measuring at least one physical or chemical parameter of a cartridge filled with a liquid substance. In a further aspect the disclosure relates to a drug delivery device equipped with such a sensor, wherein the sensor includes a planar flexible foil having a first section and having a second section separated from the first section, at least one measurement electrode located on the flexible foil, wherein the flexible foil is wrappable into a wrapped configuration in which the foil forms at least a first wrap with an inner diameter that is equal to or larger than an outer diameter of the cartridge, wherein in the wrapped configuration the first section and the second section at least partially overlap, at least one fastener located in one of the first and second section and configured to attach to the other one of the first and second sections for keeping the flexible foil in the wrapped configuration.

Abstract: A syringe body for a prefilled syringe includes: a hollow body portion; a proximal-end opening portion provided at a proximal end portion of the body portion; and a distal-end nozzle provided at a distal end portion of the body portion. The body portion is made of a cyclic olefin polymer or a cyclic olefin copolymer. The body portion has a thick body portion accounting for 80% or more of the body portion along an axial direction. A wall thickness of the thick body portion is 2.23 to 2.40 mm.

Abstract: A pre-filled syringe having containing therein at least one therapeutic is provided. The syringe contains a silicone free barrel and an elastomeric syringe stopper that is covered with an expanded polytetrafluoroethylene barrier layer. The presence of a barrier layer that is at least partially porous on the outside of the syringe stopper improves the seal between the stopper and syringe barrel and minimizes the sliding force. In some embodiments, the barrel is formed of a glass material such as a borosilicate glass, that is free of silicone or other lubricants.

Abstract: A pushing unit is stopped just before abutting against a rear end of a syringe to reliably prevent unwanted extrusion of a chemical liquid from a syringe. An injecting apparatus for injecting a chemical liquid includes: an injection head to which a syringe filled with the chemical liquid is to be mounted; a pushing unit provided on the injection head and pushing a rear end of the syringe; a rear end detection unit provided on the injection head and detecting the rear end in a contactless manner; and a control unit configured to control the injection head, the control unit acquiring a forward movement distance that the pushing unit is to be moved forward after the rear end is detected, and causing the pushing unit to move forward by the forward movement distance after the rear end is detected and to stop at a position separated from the rear end.